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Abstract
Introduction: Delivered systemically or natively circulating mesenchymal stem cells accumulate in injured tissues.
During homing mesenchymal stem cells adhere to endothelial cells and infiltrate underlying tissue. Previously we
have shown that adhesiveness of endothelial cells for mesenchymal stem cells correlates with the inhibition of
mitochondrial function of endothelial cells and secretion of von Willebrand factor. We hypothesized that von
Willebrand factor is an auto/paracrine regulator of endothelial cell adhesiveness and studied the effect of von
Willebrand factor on adhesion of mesenchymal stem cells to endothelial cells.
Methods: We used Affymetrix DNA microarrays, human protein phospho-MAPK array, Western blot, cell-based
ELISA and flow cytometry analysis to study the activation of endothelial cells by von Willebrand factor. Cell
adhesion assay and protein kinase inhibitors were used to evaluate the role of mitogen-activated protein kinases in
the regulation of endothelial cell adhesiveness for mesenchymal stem cell.
Results: Treatment of endothelial cells with von Willebrand factor stimulated the mesenchymal stem cell adhesion
in a time- and concentration-dependent manner. Mesenchymal stem cells did not adhere to immobilized von
Willebrand factor and did not express receptors for von Willebrand factor suggesting that the stimulation of the
mesenchymal stem cell adhesion is a result of endothelial cell activation with von Willebrand factor. Treatment of
endothelial cells with von Willebrand factor activated ERK-1,2 and p38 MAPK without an effect on gene or cell
surface expression of E-selectin, P-selectin, VCAM1 and ICAM1. Inhibition of p38 MAPK, but not ERK-1,2, in
endothelial cells completely abrogated the stimulation of the mesenchymal stem cell adhesion by von Willebrand
factor.
Conclusions: Von Willebrand factor is an auto/paracrine regulator of endothelial cells. Activation of p38 MAPK in
endothelial cells by von Willebrand factor is responsible for the regulation of endothelial cell adhesiveness for
mesenchymal stem cells.
Introduction
Systemically delivered or natively circulated mesenchy-
mal stem cells (MSCs) target tissues affected by radia-
tion, infarction and other kinds of trauma [1-4]. During
the homing MSCs are likely to utilize multiple mechan-
isms for recognition of injured tissues. One such
mechanism may include adhesion of MSCs to
distressed/apoptotic endothelial cells (ECs). ECs show
limited adhesiveness for cells circulating in the blood-
stream, however, they became activated after exposure
to inflammatory or stress factors. Activation of ECs
under stress conditions occurs rapidly and results in
massive release of von Willebrand factor (vWF) from
intracellular storage. Immobilization of vWF on the sur-
face of ECs and an extracellular matrix causes platelet
adhesion and aggregation. Recent studies have shown
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the regulation of stem cell homing [5]. Previously we
have shown that adhesion of human mesenchymal stem
cells (hMSCs) to ECs in vitro is regulated by endothelial
distress and apoptosis and correlates with the inhibition
of mitochondrial function in ECs and the release of
vWF [6]. In this study we demonstrate that vWF stimu-
lates p38 MAPK that regulates EC adhesiveness for
hMSCs.
Materials and methods
Reagents
Human vWF-Factor VIII free was obtained from Ameri-
can Diagnostica Inc. (Stamford, CT, USA). P38 MAPK
and ERK-1,2 inhibitors, 4-(4-fluorophenyl)-2-(4-methyl-
sulfinylphenyl)-5-(4’-pyridyl)-1-H-imidasole (SB203580),
4-ethyl-2(p-methoxyphenyl)-5-(4’-pyridyl)-1-H-imidazole
(SB202474), 2’-amino-3’-methoxyflavone (PD98059),
1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)
butadiene (U0126), were purchased from Calbiochem
(Gibbstown, NJ, USA). Neutralizing antibodies against
human P-selectin, E-selectin, ICAM1, VCAM1 and nor-
mal IgG (isotype-matching control) were purchased
from R&D Systems (Minneapolis, MN, USA).
Cell culture
Human mesenchymal stem cells (hMSCs) and human
umbilical vein endothelial cells (HUVECs) were pur-
chased from Lonza Group Ltd. (Basel, Switzerland) and
cultured in MSCGM BulletKit (Lonza) and EGM-2 Bul-
letKit (Lonza), accordingly. Passages 2 to 5 were used.
Cells were maintained at 37°C in a humidified atmo-
sphere of 5% CO2.
HMSC adhesion assay
HMSC adhesion to HUVECs was conducted as pre-
viously described [6]. HMSCs grown as a monolayer
were dissociated with trypsin-EDTA solution (Lonza),
washed with Hank’s balanced salt solution (HBSS), and
labeled with 4 μg/ml calcein AM (Molecular Probes,
Invitrogen, Carlsbad, CA, USA) in HBSS for 45 minutes
at 37°C and 5% CO2. After the labeling, hMSCs were
washed with HBSS and resuspended in Dulbecco’s mod-
ified Eagle’s medium (DMEM; Sigma, St. Louis, MO,
USA). HUVECs were prepared for the adhesion assay as
follows. A confluent monolayer of HUVECs in a 96-well
cell culture clear-bottom black plate (Corning Incorpo-
rated Life Sciences, Lowell, MA, USA) was washed twice
with HBSS and treated with vWF (0 to 6 μg/ml) in
HBSS for 0 to 9 hours at 37°C and 5% CO2.
Before the adhesion assay cells were washed with
HBSS and left in 50 μl of HBSS. HMSC suspension
(50 μl, 10,000 cells per well) was added to HUVECs and
incubated for 30 minutes at 37°C and 5% CO2. The cell
load was estimated by scanning the plate in a POLAR-
star OPTIMA microplate reader (BMG Labtech Inc.,
Cary, NC, USA) at excitation/emission wavelengths of
485/520 nm. Wells without hMSCs were used to assay
the background fluorescence. Unbound hMSCs were
aspirated and wells were washed with 200 μlo fH B S S
t w ot i m e s ,1 0 0μl HBSS was added to each well and
plates were scanned to assay a number of bound cells.
The percentage of bound cells was calculated as a ratio
between the fluorescence of washed and unwashed wells
after subtraction of the background fluorescence from
both values. At least six wells were used for each experi-
mental condition. At least three independent experi-
ments were conducted for each treatment.
Adhesion of hMSCs to collagen-coated or tissue cul-
ture plates was studied using a 96-well collagen I coated
clear-bottom black plate (BD Biosciences, Franklin
Lakes, NJ, USA) and a 96-well cell culture clear-bottom
black plate, respectively. Immobilization of vWF was
achieved by incubation of plates with a solution of vWF
(0 to 8 μg/ml) in HBSS for four hours. The adhesion of
hMSCs to the plates was assayed before and after vWF
immobilization. In order to remove unbound vWF wells
were washed with HBSS before the adhesion assay.
Immobilization of vWF on collagen I coated and tissue
culture plates was monitored by ELISA. Plates were
treated with vWF as described above, washed three
times with the wash buffer from ELISA development kit
(R&D Systems) and incubated with peroxidase-
conjugated rabbit polyclonal anti-human vWF antibody
(Dako North America, Inc., Carpinteria, CA, USA)
according to the manufacturer’s recommendations.
ELISA was developed and the optical densities were
measured at 450 nm with a 595 nm reference wave-
length in a POLARstar OPTIMA microplate reader
(BMG Labtech Inc., Cary, NC, USA). Immobilization of
vWF was determined using eight measurements per
each experimental condition.
In experiments on the inhibition of p38 MAPK and
ERK-1,2 HUVECs were pre-incubated with inhibitors of
protein kinases for 45 minutes and then stimulated with
vWF. Activity of p38 MAPK was inhibited with
SB203580. SB202474, a chemical analog of SB203580,
was used as a negative control. Phosphorylation and
activation of ERK-1,2 was inhibited with U0126 or
PD98059.
Flow cytometric analysis of antigen expression on the
surface of hMSCs and HUVECs
Analysis of E-selectin, VCAM1 and ICAM1 expression
on the surface of HUVECs and integrin avb3 and GPIba
expression on the surface of hMSCs was conducted
using flow cytometry. Cells were dissociated and resus-
pended in the flow cytometry buffer consisting of 2%
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(Sigma-Aldrich, St. Louis, MO, USA) in Dulbecco’s
phosphate buffered saline (PBS; Sigma). HUVECs were
dissociated using Hank’s based enzyme free cell disso-
ciation solution (Millipore, Billerica, MA, USA). HMSCs
were dissociated with trypsin-EDTA solution (Lonza).
Cells (2 × 10
5 cells) were stained with corresponding
fluorochrome-conjugated monoclonal antibodies (BD
Biosciences) for 30 minutes at room temperature
according to the manufacturer’s recommendations. After
incubation with antibodies, cells were washed with 5 ml
of the flow cytometry buffer and resuspended in the
flow cytometry buffer containing 1% paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA, USA).
Background staining was assessed by incubation of cells
with mouse fluorochrome- and isotype-matching immu-
noglobulins. Flow cytometric analysis was performed by
acquiring 5,000 events on a FACScan flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA). Data were
processed with a CellQuest™software package supplied
by instrument manufacturer (BD Biosciences, Franklin
Lakes, NJ, USA). The cellular debris was assessed on the
basis of forward and right angle scattering analysis and
excluded from further analysis by a CellQuest™software
package (BD Biosciences, Franklin Lakes, NJ, USA).
Human phospho-MAPK array
Analysis of protein kinase phosphorylation in HUVECs
treated with vWF was conducted using the human
phospho-MAPK array kit (R&D Systems). Confluent
HUVECs grown on a 100 mm tissue culture plate were
washed twice with HBSS and treated with 4 μg/ml vWF
in HBSS for 0 to 35 minutes. After the treatment cells
were washed with HBSS and lysed with the manufac-
turer supplied buffer and protein, phosphorylation was
developed according to the manufacturer’s recommen-
dations. Phosphorylation of protein kinases was detected
by exposure of phospho-MAPK array to X-ray film
(Kodak, Rochester, NY, USA). All arrays from the same
experiment were processed simultaneously and exposed
to the same X-ray film.
Western blot analysis of p38 MAPK and ERK-1,2
phosphorylation
Confluent HUVECs grown on a 100 mm tissue culture
plate were washed twice with HBSS, treated with 4 μg/
ml vWF in HBSS for 0 to 5 minutes and lysed with
1 ml of lysis buffer containing 0.025 M Tris-HCl, pH
7.4, 0.15 M NaCl, 5 mM EDTA, 1% Triton X-100, 0.5%
N o n i d e tP - 4 0 ,a n das e to fp r o t e a s ei n h i b i t o r s( R o c h e
Applied Science, Indianapolis, IN, USA) and phospha-
tase inhibitors (cocktails type 1 and 2) (Sigma) for
15 minutes at 4°C. Extract was cleared by centrifugation
at 15,000 × g at 4°C for 30 minutes. Proteins (25 μg)
were separated in Bis-Tris 10% Criterion gel (Bio-Rad,
Hercules, CA, USA) using XT MOPS running buffer
(Bio-Rad) and transferred to a nitrocellulose membrane
(Bio-Rad). Western blot was performed using polyclonal
antibodies against phosphorylated p38 MAPK (Thr180/
Tyr182), total p38 MAPK, phosphorylated ERK-1,2
(Thr202/Tyr204) and total ERK-1,2 (Cell Signaling
T e c h n o l o g y ,D a n v e r s ,M A ,U S A ) .W e s t e r nb l o tw a s
developed with Rabbit TrueBlot HRP-labeled anti-rabbit
antibody (eBioscience, San Diego, CA, USA) and ECL
Western blotting detection reagents (GE Healthcare UK
Limited, Pittsburgh, PA, USA).
Cell-based ELISA for p38 MAPK and ERK-1,2
phosphorylation in HUVECs treated with vWF
Phosphorylation of p38 MAPK (Thr180/Tyr182) and
ERK-1,2 (Thr202/Tyr204) was assayed using corre-
sponding cell-base ELISA kits (R&D Systems). Confluent
HUVECs grown on a 96-well cell culture clear-bottom
black plate were washed twice with HBSS and treated
with 0 to 6 μg/ml vWF in HBSS for four hours. After
the treatment, cells were washed with HBSS, fixed with
4% paraformaldehyde in phosphate-buffered saline for
30 minutes and stained according to the manufacturer’s
recommendations. Fluorescence of total protein kinase
at 450 nm and phosphorylated protein kinase at 600 nm
were acquired in a POLARstar OPTIMA microplate
reader. Background fluorescence was estimated as
recommended by the manufacturer from the control
wells stained with corresponding secondary antibody
and the relative ratio of the fluorescence of phosphory-
lated protein kinase to the fluorescence of total protein
kinase was calculated. At least six wells were used for
each experimental condition.
Activity assays of p38 MAPK and ERK-1,2
Activities of p38 MAPK and ERK-1,2 in HUVEC lysate
were assayed using the p38 and p44/42 MAPK assay
kits (Cell Signaling Technology). Confluent HUVECs
grown on a six-well cell culture plate were washed twice
with HBSS and treated with 0 to 6 μg/ml vWF in HBSS
for four hours. After the treatment cells were washed
with HBSS and lysed with the provided buffer according
to the manufacturer’s recommendations. Phosphorylated
p38 MAPK (Thr180/Tyr182) and ERK-1,2 (Thr202/
Tyr204) were immunoprecipitated from HUVEC lysates
of equal volume (1 ml) and protein concentrations
(1.5 mg/ml) with corresponding anti-phospho-p38
MAPK (Thr180/Tyr182) and anti-phospho ERK-1,2
(Thr202/Tyr204) antibodies supplied by the manufac-
turer. Enzymatic activities of immunoprecipitated
protein kinases were assayed using recombinant
ATF-2 protein as a substrate for p38 MAPK and recom-
binant Elk-1 protein as a substrate for ERK-1,2.
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detected by Western blots. For this, reaction mixtures
(35 μl) were separated in Bis-Tris 10% Criterion gel using
XT MOPS running buffer and transferred to a nitrocellu-
lose mem-brane. Western blot was performed using anti-
phospho-ATF-2 (Thr71) or anti-phospho-Elk-1 (Ser383)
antibodies. Immunoreactive bands were visualized using
affinity purified HRP-labeled goat anti-rabbit F(ab’)2 frag-
ment antibody (Kirkegaard and Perry Laboratories,
Gaithersburg, Maryland, USA) and ECL Western blotting
detection reagents (GE Healthcare UK Limited).
Affymetrix DNA microarray analysis
RNA was extracted from HUVECs using the RNeasy kit
(Qiagen, Germantown, MD, USA), and analysis of gene
expression in HUVECs was performed on Affymetrix
Human Genome U133 Plus 2.0 array (Santa Clara, CA,
USA) according to the manufacturer’s recommenda-
tions. Raw microarray data were processed with the affy
package of the Bioconductor project using MAS 5.0
algorithm and subjected to t-test.
Analysis of DNA content using Quanti-iT PicoGreen
dsDNA reagent
HUVECs were treated with vWF and inhibitors of pro-
tein kinases as described above and washed with HBSS.
To prepare the cell lysate 100 μl of cell lysis solution
(0.2% v/v Triton X-100, 10 mM Tris (ph 7.0), 1 mM
E D T A )w a sa d d e dt oe a c hw e l l(96-well plate), and the
plate was process through a total of two freeze at -80°C/
thaw at room temperature cycles. After a final thaw
100 μl of the aqueous working solution of Quant-iT
PicoGreen dsDNA reagent (Invitrogen) prepared accord-
ing the manufacturer’s instructions was added to each
well. Fluorescence was measured using a Polarstar
OPTIMA microplate reader (BMG Labtech Inc.) at exci-
tation/emission wavelengths of 485/520 nm. DNA stan-
dard curve was generated using dsDNA standard
provided with the Picogreen Assay kit and used for
determining the DNA concentration of the samples.
Confocal imaging
Confluent monolayer of HUVECs on Lab-Tek II cham-
ber CC2 glass slides (Nalge Nunc International, Roche-
ster, NY, USA) was treated with 4 μg/ml vWF in HBSS
for four hours and the adhesion assay with hMSCs was
conducted as described in the hMSC adhesion assay sec-
tion. Cells were fixed with 5% paraformaldehyde, per-
meabilized with 0.1% Triton x100 in phosphate buffered
saline, blocked with 5 mg/ml bovine serum albumin in
PBS for one hour and stained with 1 μg/ml AF488-con-
jugated CD31 antibody (BD Pharmingen, Franklin
Lakes, NJ, USA), the specific antigen marker of
HUVECs, and 1 μg/ml PE-conjugated CD90 antibody
( B DP h a r m i n g e n ) ,t h es p e c i f i ca n t i g e nm a r k e ro f
hMSCs, for four hours. After staining cells was washed
with PBS and images were acquired on Olympus Fluo-
View FV1000 confocal microscope (Olympus America
Inc. Center Valley, PA, USA).
Results
VWF regulates hMSC adhesion to HUVECs
Previously we have shown that endothelial distress
potentiates the hMSC adhesion [6]. The adhesion of
hMSCs to distressed/apoptotic HUVECs correlated with
the secretion of vWF by ECs suggesting that vWF may
regulate the interaction of hMSCs with ECs [6].
In order to study the effect of vWF on the hMSC
adhesion HUVECs were treated with exogenous vWF.
Treatment of HUVECs with vWF was conducted in
HBSS to eliminate the interference from vWF present in
fetal bovine serum. Plates were washed before the adhe-
sion assay in order to remove unbound vWF. Since
hMSCs respond to endothelial distress [6], and serum
deprivation itself is a stress factor, we also tested
whether HBSS alone affects the hMSC adhesion.
VWF stimulated hMSC adhesion to HUVECs in a
time and dose-dependent manner (Figure 1). Incubation
of HUVECs with HBSS for four hours stimulated the
hMSC adhesion 1.3-fold (Figure 1a), which was less
than the stimulation caused by the treatment with vWF
(2.4-fold). Microscopic examination has shown that
hMSCs adhere to HUVECs and are located on the top
of endothelial monolayer within the boundaries of ECs.
Exemplar confocal image of hMSCs adhered to
HUVECs treated with vWF is shown in Figure 2. These
data argue that vWF regulates hMSC adhesion to ECs.
HMSCs do not express glycoprotein 1ba, integrin aVb3
and do not adhere to immobilized vWF
Since the presence of soluble vWF was not required for
the stimulation of the MSC adhesion, it was conceivable
that the MSC adhesion is regulated by MSC interaction
with vWF bound to the endothelial surface or an extra-
cellular matrix. A similar mechanism was suggested for
the stimulation of platelet adhesion and aggregation by
immobilized vWF [7,8]. Known receptors for vWF
include platelet glycoprotein Ib (GPIba, expressed on
the surface of platelets) and aVb3 integrin (expressed on
the surface of platelets and ECs) [7,8]. We, therefore,
tested whether hMSCs express receptors for vWF (aVb3
integrin and GPIba) and adhere to immobilized vWF.
Expression of aVb3 integrin and GPIba on the surface
of hMSCs was tested by flow cytometric analysis. We
found that hMSCs are negative for the expression of
integrin aVb3 and GPIba (Figure 3). Adhesion of MSCs
to vWF was studied after vWF immobilization on tissue
culture treated (plastic) or collagen I coated cell culture
Potapova et al. Stem Cell Research & Therapy 2010, 1:35
http://stemcellres.com/content/1/5/35
Page 4 of 11plates. The insert in Figure 4 shows that nearly equal
amounts of vWF were immobilized on plastic or col-
lagen I surfaces after treatment of plates with 0 to
8 μg/ml vWF for four hours. Immobilization of vWF
onto plastic plate did not affect hMSC adhesion (Figure
4). HMSCs adhered 3.3 times better to collagen I coated
plate than to tissue culture treated plate. Immobilization
of vWF on collagen I coated plate inhibited hMSC adhe-
sion (Figure 4) indicating that hMSCs and vWF compete
for the binding to collagen I.
Taken together, the data of flow cytometry and the
adhesion assay suggest that hMSCs do not directly
interact with immobilized vWF, presumably, due to the
lack of vWF receptors on the surface of hMSCs.
Adhesion of hMSCs to HUVECs activated with vWF does
not depend on overexpression of the adhesion molecules
on the endothelial surface
Lack of direct adhesion of hMSCs to immobilized vWF
suggested that the stimulation of the hMSC adhesion is a
result of an activation of ECs with vWF. Activation of ECs
may occur as a consequence of de novo transcription,
synthesis and delivery of adhesion molecules (E-selectin,
P-selectin, VCAM1 or ICAM1) to the cell surface [9].
In order to evaluate the effect of vWF on gene expres-
sion in HUVECs we used Affymetrix DNA microarrays.
The set of Affymetrix Human Genome U133 Plus 2.0
arrays (GEO accession (GEO:GSE19816)) included
HUVECs maintained in EGM2 growth media (three
Figure 1 VWF stimulates HUVEC adhesiveness for hMSCs. (a) Shows changes in HUVEC adhesiveness for hMSCs caused by treatment with
4 μg/ml vWF (black circle) or HBSS (white circle) for 0 to 9 hours. Asterisks mark time points where adhesion of hMSCs to HUVECs treated with
vWF was different (t-test, P-value <0.05) from the adhesion to HUVECs maintained in HBSS. (b) Shows the dose-response curve of HUVEC
adhesiveness for hMSCs after treatment of HUVECs with 0 to 6 μg/ml vWF for four hours. Data are shown as mean ± SD of eight independent
measurements.
Figure 2 Image of hMSCs adherent to a confluent monolayer
of HUVECs treated with vWF. Confocal image of a planar (a) and
Z-axis (b) projections of hMSCs adherent to HUVECs treated with
4 μg/ml vWF for four hours. HUVECs were stained with AF488-
conjugated CD31 (green). HMSCs were labeled with PE-conjugated
CD90 (red). HMSCs were found on the top of endothelial monolayer
within the boundaries of ECs.
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three microarrays) and HUVECs treated with vWF
(4 μg/ml vWF, four hours, three microarrays). Expres-
sion of 340 genes was affected by more than two-fold
(P-value < = 0.05) in HUVECs treated with HBSS in
comparison with HUVECs maintained in EGM2 growth
media. Treatment of HUVECs with vWF changed the
expression of 157 genes by more than two-fold in com-
parison with HBSS (Additional file 1) and 567 genes in
comparison with EGM2 growth media (Additional file
2). Gene expression of E-selectin, P-selectin, VCAM1
and ICAM1 was not affected by serum starvation or by
treatment of HUVECs with vWF.
Flow cytometric analysis showed that the expression of
E-selectin, P-selectin, VCAM1 or ICAM1 on the surface
of ECs was not upregulated by treatment of HUVECs
with HBSS or vWF (Figure 5) suggesting that upregula-
tion of the adhesion molecules on the surface of ECs was
not the reason for the stimulation of the hMSC adhesion.
In order to further evaluate the role of adhesion mole-
cules in the regulation of hMSC adhesion to HUVECs
treated with vWF ECs were incubated with 10 μg/ml
neutralizing antibodies against E-selectin, P-selectin,
VCAM1, ICAM1 or isotype-matching control (IgG) for
40 minutes before the adhesion assay (Figure 6). Neutra-
lizing antibodies and isotype-matching control had no
effect on hMSC adhesion to HUVECs treated with vWF.
Data of DNA microarrays, flow cytometry and treat-
ment of HUVECs with neutralizing antibodies argue
that the stimulation of hMSC adhesion by vWF is not
related to cell surface expressions of E-selectin, P-selec-
tin, VCAM1 or ICAM1 in ECs.
VWF induces the phosphorylation and activation of p38
MAPK and ERK-1,2 in HUVECs
Considering that hMSCs do not directly interact with
immobilized vWF and the stimulation of EC adhesiveness
for hMSCs is not related to overexpression of adhesion
Figure 3 Expression of aVb3 integrin and platelet glycoprotein Iba on the surface of hMSCs. (a and b) Show the results of flow
cytometric analysis of integrin avb3 ((a), green histogram) and platelet glycoprotein Iba (GPIb, (b), green histogram) expression on the surface of
hMSCs. Red histograms represent fluorochrome matching isotype controls.
Figure 4 Effect of vWF on adhesion of hMSCs to collagen I
coated or tissue culture treated plastic plates. Adhesion of
hMSCs to collagen I coated and tissue culture plates was measured
before and after immobilization of vWF. Before the adhesion assay
vWF was removed and plates were washed with HBSS. Asterisks
mark statistically significant differences compared to collagen I
coated plate (t-test, P-value <0.05). Data are shown as mean ± SD
of eight independent measurements. The insert shows vWF
immobilization on collagen I coated (black circle) and tissue culture
(white circle) plates exposed to 0 to 8 μg/ml vWF in HBSS for four
hours. Immobilization of vWF was measured by ELISA and is shown
in relative units (RU) as mean ± SD of eight independent
measurements.
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the effect of vWF on EC adhesiveness is mediated by sig-
nal transduction pathways triggered in HUVECs by expo-
sure to vWF.
In order to identify signaling pathways involved in the
regulation of EC adhesiveness for hMSCs we studied the
activation of protein kinases in HUVECs stimulated
with vWF. Analysis of protein phosphorylation using the
human phospho-MAPK arrays demonstrated that treat-
ment of HUVECs with 4 μg / m lv W Ff o r0t o3 5m i n -
utes resulted in the phosphorylation of p38a MAPK and
p38g MAPK as well as ERK-1 and ERK-2 (Figure 7a).
Phosphorylation of p38 MAPK and ERK-1,2 was verified
by Western blot analysis (Figure 7b). Quantification of
p38 MAPK and ERK-1,2 phosphorylation in HUVECs
treated with 0 to 6 μg/ml vWF for four hours was per-
formed using corresponding cell-based ELISAs. Data in
Figure 7c show that vWF stimulated the phosphoryla-
tion of p38 MAPK and ERK-1,2 in HUVECs in a dose-
dependent manner. After treatment of HUVECs for four
hours with 6 μg/ml vWF the level of p38 MAPK phos-
phorylation was increased 1.8-fold (P-value <0.05) in
comparison with HUVECs in HBSS (Figure 7c). The
increase in the level of ERK-1,2 phosphorylation after
treatment of HUVECs with vWF was smaller (1.2-fold)
but statistically significant (Figure 6c, P-value <0.05).
Next, we tested whether the phosphorylation of p38
MAPK and ERK-1,2 in HUVECs treated with vWF sti-
mulates their enzymatic activities. HUVECs were treated
with 0 to 6 μg/ml vWF for four hours, phosphorylated
forms of p38 MAPK and ERK-1,2 were immunoprecipi-
tated from cell lysates and used to assay their enzymatic
activities. Activity of p38 MAPK was measured using
recombinant ATF-2 protein. Recombinant Elk-1 protein
was employed to test the activity of ERK-1,2. Represen-
tative Western blots of phospho-ATF-2 and phospho-
Elk-1 are shown in Figure 8a. Densitometric analysis of
ATF-2 and Elk-1 phosphorylation is shown in Figure 8b.
Enzymatic activities of p38 MAPK and ERK-1,2 were
stimulated by vWF in a dose-dependent manner. After
Figure 5 Expression of E-selectin, P-selectin, VCAM1 and ICAM1 on the surface of HUVECs treated with vWF. HUVECs were treated with
4 μg/ml vWF in HBSS for four hours. Expression of E-selectin (a), VCAM1 (b), ICAM1 (c) and P-selectin (d) on the surface of HUVECs maintained
in EGM2 growth media (red histogram), incubated with HBSS (green histogram) or treated with vWF (blue histogram) was analyzed by flow
cytometry.
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activities of both p38 and ERK-1,2 were increased
2.4-fold (P-value <0.05).
Analysis of signal transduction pathways activated in
response to treatment of ECs with vWF revealed that
vWF stimulates the phosphorylation and activation of
p38 MAPK and ERK-1,2 in HUVECs.
P38 MAPK regulates adhesion of hMSCs to HUVECs
activated with vWF
In order to investigate the role of p38 MAPK and ERK-
1,2 in the regulation of EC adhesiveness for hMSCs we
studied the effects of selective inhibitors of p38 MAPK
(SB203580) and ERK-1,2 (PD98059 and U0126) on
hMSC adhesion to HUVECs treated with 4 μg/ml vWF
for four hours.
Inhibitors of ERK-1,2 (PD98059 and U0126, 10 μM)
showed a small stimulation of hMSC adhesion (approxi-
mately 1.2-fold, P-value <0.05) to HUVECs maintained in
HBSS and had no effect on hMSC adhesion to HUVECs
treated with vWF (Figure 9a). Effect of SB203580 on
hMSC adhesion to HUVECs in HBSS was not statistically
significant. SB203580, but not its inactive analog
SB202474, at 10 μM reduced vWF-induced stimulation of
hMSC adhesion to HUVECs by 70% (Figure 9a, P-value
<0.05). Data in Figure 9b show that SB203580 inhibited
the stimulation of the hMSC adhesion by vWF in a dose-
dependent manner (Figure 9b). At 10 to 20 μM SB203580
completely eliminated vWF-induced stimulation of hMSC
adhesion to HUVECs (Figure 9b).
Visual examination under the microscope showed that
the monolayer of HUVECs remains intact at all experi-
mental conditions described above. Cellular DNA content
per well was measured to confirm that protein kinase inhi-
bitors and vWF do not affect an endothelial monolayer.
Data in Figure 10 show that the same number of cells
remains in each well after exposure of HUVECs to protein
kinase inhibitors in the absence and presence of vWF.
Data with the inhibitors of protein kinases strongly
suggest that the activation of p38 MAPK by vWF in
ECs is involved in the regulation of the hMSC adhesion.
Discussion
Exposure of ECs to inflammatory and other stress fac-
tors is a powerful stimulator of cell adhesion. In
response to stress, ECs release vWF that binds to EC
surface or an extracellular matrix. Interaction of plate-
lets with immobilized vWF triggers signal transduction
pathways mediated by GPIb-V-IX complex [8], aIIbb3
and avb3 integrins [10] and leads to platelet adhesion
and aggregation [8,10]. In contrast to platelets, the adhe-
sion of leukocytes is mainly regulated by the expression
of adhesion molecules on the surface of ECs as the
result of de novo protein synthesis [9].
MSCs respond poorly to the activation of ECs with
inflammatory factors (tumor necrosis factor (TNF)-a or
interleukin (IL)-1b) and their adhesion does not corre-
late with the expression of adhesion molecules on the
endothelial surface [6]. At the same time, TNF-a and
IL-1b stimulate hMSC adhesion to ECs in the presence
of inhibitors of RNA or protein synthesis [6]. The MSC
adhesion is also significantly potentiated by other pro-
apoptotic agents, like staurosporine, wortmannin and
okadaic acid, suggesting that endothelial distress and
apoptosis may play a crucial role in the regulation of
MSC adhesion to ECs [6]. Adhesion of MSCs to dis-
tressed/apoptotic ECs correlates with the secretion of
vWF by ECs indicating that vWF may be involved in
the regulation of the MSC adhesion [6].
Treatment of ECs with exogenous vWF potentiated the
adhesion of MSCs. The presence of vWF in the media
during the adhesion assay was not required for the stimu-
lation of the MSC adhesion. It was conceivable that vWF
binds to an extracellular matrix or to the surface of
endothelial cells, stimulates MSCs and promotes the MSC
adhesion. However, the immobilization of vWF on col-
lagen I inhibited MSC adhesion to collagen I coated plates
suggesting that MSCs and vWF compete for the binding
Figure 6 Treatment of HUVECs with neutralizing antibodies
against E-selectin, P-selectin, VCAM1 and ICAM1. Endothelial
cells were treated with 4 μg/ml vWF in HBSS for four hours and
exposed to 10 μg/ml matching isotype-control (IgG) or 10 μg/ml
neutralizing antibodies against E-selectin, P-selectin, VCAM1 or
ICAM1 for 40 minutes before hMSC adhesion assay. Data are shown
as mean ± SD of eight independent measurements.
Isotype-matching control and neutralizing antibodies against E-
selectin, P-selectin, VCAM1 or ICAMP1 had no significant affect on
hMSC adhesion to HUVECs treated with vWF (t-test, P-value >0.05).
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the cell surface expression of aVb3 integrin and GPIba,
the receptors for vWF, on MSCs. Collectively, these results
suggest that vWF does not stimulate MSC adhesiveness,
presumably, due to the absence of direct interaction of
MSCs with immobilized vWF.
Since MSCs do not adhere to immobilized vWF, we
hypothesized that vWF stimulates the MSC adhesion via
an activation of ECs. The known mechanism of EC acti-
vation assumes the stimulation of de novo synthesis and
the expression of the adhesion molecules on the endothe-
lial surface. Experiments with ECs treated with vWF
showed that vWF affects gene expression in ECs.
However, in contrast to the activation of ECs with
inflammatory factors, treatment of ECs with vWF did not
stimulate gene expression of E-selectin, P-selectin,
ICAM1 or VCAM1 and did not upregulate the expres-
sion of E-selectin, P-selectin, ICAM1 or VCAM1 on the
surface of ECs. These results suggest that the mechanism
of EC activation by vWF is different from that described
for the activation of ECs with inflammatory factors.
Considering that the activation of ECs with vWF did not
rely on the expression of the adhesion molecules we
hypothesized that the mechanism of ECs activation is
similar to that described for the activation of platelets. It is
known that platelet adhesiveness is mediated by binding of
vWF with the surface of platelets and activation of signal
transduction pathways. The binding of vWF with platelets
Figure 7 Phosphorylation of protein kinases in HUVECs treated with vWF. Protein phosphorylation in HUVECs treated with vWF was
analysed using the human phospho-MAPK array, by Western blot and cell-based ELISAs. (a) Shows the phosphorylation of eighteen protein
kinases in HUVECs treated with 4 μg/ml vWF for 0 to 35 minutes assayed using the human phospho-MAPK array. VWF stimulated the
phosphorylation of ERK-2 (spots 1), ERK-1 (spots 2), p38a (spots 3) and p38g (spots 4). Spots labelled with number 5 are the positive controls
used for the normalization of the arrays. (b) Shows Western blots of total p38 MAPK and ERK-1,2 and phosphorylated p38 MAPK and ERK-1,2
from lysates of HUVECs treated with 4 μg/ml vWF for 0-5 min. (c) Shows the dose-response curves of p38 MAPK (black circle) and ERK-1,2 (white
circle) phosphorylation in HUVECs treated with 0 to 6 μg/ml vWF for four hours measured using the cell-based ELISAs. Data are shown as mean
± SD of four independent measurements. Asterisks mark statistically significant changes in comparison with none treated HUVECs (t-test, P-value
<0.05).
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plex [8], aIIbb3 and avb3 integrins [10] and lead to the acti-
vation of mitogen-activated protein kinases [8,10]
including the activation of ERK-1,2 and p38 MAPK
[11,12]. The activation of p38 MAPK in platelets may play
a decisive role in the regulation of platelet adhesion and
aggregation by vWF [11,12]. Analysis of protein kinase
phosphorylation in ECs revealed that treatment with vWF
resulted in the phosphorylation and activation of p38
MAPK and ERK-1,2. The inhibition of p38 MAPK, but
Figure 8 ERK-1,2 and p38 MAPK activity assays in lysates of HUVECs treated with vWF. HUVECs were treated with 0 to 6 μg/ml vWF for
four hours. Phosphorylated p38 MAPK and ERK-1,2 were immunoprecipitated from HUVEC lysates and their enzymatic activities were analyzed
using their specific substrates, ATF-2 and Elk-1, respectively. (a) Shows representative Western blots of phospho-ATF-2 and phospho-Elk-1. (b)
Shows the results of densitometric analysis of Western blots of phosphorylated ATF-2 (black circle) and Elk-1 (white circle). Data are shown as
mean ± SD of three independent experiments.
Figure 9 Effects of p38 MAPK and ERK-1,2 inhibitors on hMSC adhesion to HUVECs treated with vWF. HUVECs were pre-incubated with
p38 MAPK inhibitor SB203580 (10 μM), its inactive analog SB202474 (10 μM) or the inhibitors of ERK-1,2 phosphorylation, PD98059 (10 μM) or
U0126 (10 μM), for 45 minutes and treated with 4 μg/ml vWF for four hours in the presence of the protein kinase inhibitors. (a) Shows the
effects of the protein kinase inhibitors on hMSC adhesion to HUVECs treated with and without vWF. Data are shown as mean ± SD of eight
independent measurements. Single asterisks mark statistically significant changes in hMSC adhesion in comparison with HUVECs not treated with
vWF (t-test, P-value <0.05). Treatment of HUVECs with vWF in the presence of SB203580 resulted in the inhibition of hMSC adhesion in
comparison with hMSC adhesion to HUVECs treated with vWF alone (double asterisks, t-test, P-value <0.05) or in comparison with hMSC
adhesion to HUVECs treated with vWF in the presence of SB202474 (pound key, t-test, P-value <0.05). (b) Shows the dose-dependent effect of
SB203580 (0 to 20 μM) on hMSC adhesion to HUVECs treated with (white circle) and without (black circle) vWF. Data are shown as mean ± SD
of eight independent measurements. Asterisks mark data point with statistically significant difference from HUVECs maintained in HBSS.
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of vWF on EC adhesiveness for MSCs. Thus, studies of
signal transduction pathways triggered by vWF in ECs
showed that vWF activates ECs via a mechanism similar
to that described for the stimulation of platelets. Inhibition
of vWF-dependent stimulation of the MSC adhesion by
selective inhibitor of p38 MAPK suggested that p38
MAPK plays a crucial role in the modulation of EC adhe-
siveness for MSCs by vWF.
Conclusions
VWF is an autocrine/paracrine effector of signal transduc-
tion and gene expression in ECs that regulates EC adhe-
siveness for MSCs via activation of p38 MAPK in ECs.
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Figure 10 Effects of protein kinase inhibitors and vWF on a
number of endothelial cells in adhesion wells. HUVECs were pre-
incubated with p38 MAPK inhibitor SB203580 (10 μM), its inactive
analog SB202474 (10 μM) or the inhibitors of ERK-1,2
phosphorylation, PD98059 (10 μM) or U0126 (10 μM), for 45 minutes
and treated with 4 μg/ml vWF for four hours in the presence of the
protein kinase inhibitors. The mock adhesion assay was conducted
without addition of hMSCs. The number of cells in the wells was
assayed using Quanti-iT PicoGreen dsDNA reagent as described in
the Materials and Methods. Data are shown as mean ± SD of eight
independent measurements. Treatment of HUVECs with protein
kinase inhibitors and vWF had no significant effect on a number of
endothelial cells in adhesion wells (t-test, P-value >0.05).
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